Literature DB >> 31028129

A brief history of "Alzheimer disease": Multiple meanings separated by a common name.

David S Knopman1, Ronald C Petersen2, Clifford R Jack2.   

Abstract

The field of Alzheimer disease (AD) has a nosologic problem: The diagnostic label "Alzheimer disease" has several distinctive meanings. The term probable AD was introduced in 1984 to designate a clinically diagnosed acquired and progressive amnestic dementia for which there was no evidence for another etiology. Probable AD represented a clinicopathologic entity that assumed a specific and sensitive linkage between amnestic dementia and the neuropathology of β-amyloid-containing neuritic plaques and tau-containing neurofibrillary tangles. The clinicopathologic model represented by probable AD was adapted in abbreviated form for population-based studies and general clinical practice, although the uncertainty connoted by "probable" was often overlooked. Representing the growing public awareness of later life cognitive impairment, a vernacular meaning of AD arose out of the clinicopathologic model in which AD represented all dementia not due to another clinically apparent cause. In contrast, by the 1990s, neuropathologists settled on a definition of AD based entirely on a sufficient burden of neuritic plaques and neurofibrillary tangles at postmortem examination, regardless of antemortem clinical status. In the last decade, the availability of fluid and imaging biomarkers that measure β-amyloid and tau abnormalities has enabled antemortem pathobiological diagnoses, highlighting the divide between the clinicopathologic model, the vernacular usage, and the pathobiological models. Each definition has value. However, the meanings of AD as defined by each of these models are not interchangeable. The pathobiological one is the only one that is unambiguous.
© 2019 American Academy of Neurology.

Entities:  

Mesh:

Year:  2019        PMID: 31028129      PMCID: PMC6556090          DOI: 10.1212/WNL.0000000000007583

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  66 in total

1.  Mild cognitive impairment: clinical characterization and outcome.

Authors:  R C Petersen; G E Smith; S C Waring; R J Ivnik; E G Tangalos; E Kokmen
Journal:  Arch Neurol       Date:  1999-03

2.  The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Marilyn S Albert; Steven T DeKosky; Dennis Dickson; Bruno Dubois; Howard H Feldman; Nick C Fox; Anthony Gamst; David M Holtzman; William J Jagust; Ronald C Petersen; Peter J Snyder; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

3.  Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010.

Authors:  Thomas G Beach; Sarah E Monsell; Leslie E Phillips; Walter Kukull
Journal:  J Neuropathol Exp Neurol       Date:  2012-04       Impact factor: 3.685

4.  Very mild Alzheimer's disease: informant-based clinical, psychometric, and pathologic distinction from normal aging.

Authors:  J C Morris; D W McKeel; M Storandt; E H Rubin; J L Price; E A Grant; M J Ball; L Berg
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

5.  Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE ε4 haplotype status: a community-based cohort study.

Authors:  Hyun-Sik Yang; Lei Yu; Charles C White; Lori B Chibnik; Jasmeer P Chhatwal; Reisa A Sperling; David A Bennett; Julie A Schneider; Philip L De Jager
Journal:  Lancet Neurol       Date:  2018-08-06       Impact factor: 44.182

6.  Mild cognitive impairment in the elderly: predictors of dementia.

Authors:  C Flicker; S H Ferris; B Reisberg
Journal:  Neurology       Date:  1991-07       Impact factor: 9.910

7.  Brain lesions at autopsy in older Japanese-American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu-Asia aging study.

Authors:  Lon White
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

8.  Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  D S Knopman; S T DeKosky; J L Cummings; H Chui; J Corey-Bloom; N Relkin; G W Small; B Miller; J C Stevens
Journal:  Neurology       Date:  2001-05-08       Impact factor: 9.910

9.  Tau positron emission tomographic imaging in aging and early Alzheimer disease.

Authors:  Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling
Journal:  Ann Neurol       Date:  2015-12-15       Impact factor: 10.422

10.  Assessing the economic burden of Alzheimer's disease patients first diagnosed by specialists.

Authors:  Noam Y Kirson; Urvi Desai; Ljubica Ristovska; Alice Kate G Cummings; Howard G Birnbaum; Wenyu Ye; J Scott Andrews; Daniel Ball; Kristin Kahle-Wrobleski
Journal:  BMC Geriatr       Date:  2016-07-11       Impact factor: 3.921

View more
  10 in total

1.  Blood-brain barrier link to human cognitive impairment and Alzheimer's Disease.

Authors:  Giuseppe Barisano; Axel Montagne; Kassandra Kisler; Julie A Schneider; Joanna M Wardlaw; Berislav V Zlokovic
Journal:  Nat Cardiovasc Res       Date:  2022-02-07

Review 2.  Alzheimer's disease.

Authors:  Philip Scheltens; Bart De Strooper; Miia Kivipelto; Henne Holstege; Gael Chételat; Charlotte E Teunissen; Jeffrey Cummings; Wiesje M van der Flier
Journal:  Lancet       Date:  2021-03-02       Impact factor: 79.321

Review 3.  Extracellular Vesicles: A Possible Link between HIV and Alzheimer's Disease-Like Pathology in HIV Subjects?

Authors:  Sunitha Kodidela; Kelli Gerth; Sanjana Haque; Yuqing Gong; Saifudeen Ismael; Ajay Singh; Ishrat Tauheed; Santosh Kumar
Journal:  Cells       Date:  2019-08-24       Impact factor: 6.600

4.  Dementia and Major Neurocognitive Disorders: Some Lessons Learned One Century after the first Alois Alzheimer's Clinical Notes.

Authors:  Donatella Rita Petretto; Gian Pietro Carrogu; Luca Gaviano; Lorenzo Pili; Roberto Pili
Journal:  Geriatrics (Basel)       Date:  2021-01-11

5.  Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE ε4, and Cognitive Impairment.

Authors:  Joseph Therriault; Tharick A Pascoal; Andrea L Benedet; Cecile Tissot; Melissa Savard; Mira Chamoun; Firoza Lussier; Min Su Kang; Gleb Berzgin; Tina Wang; Jaime Fernandes-Arias; Gassan Massarweh; Jean-Paul Soucy; Paolo Vitali; Paramita Saha-Chaudhuri; Serge Gauthier; Pedro Rosa-Neto
Journal:  Neurology       Date:  2020-12-21       Impact factor: 9.910

6.  Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review.

Authors:  Jetske van der Schaar; Leonie N C Visser; Femke H Bouwman; Johannes C F Ket; Philip Scheltens; Annelien L Bredenoord; Wiesje M van der Flier
Journal:  Alzheimers Res Ther       Date:  2022-02-10       Impact factor: 6.982

Review 7.  Biomarkers for the Diagnosis of Alzheimer's Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria.

Authors:  Maciej Dulewicz; Agnieszka Kulczyńska-Przybik; Piotr Mroczko; Johannes Kornhuber; Piotr Lewczuk; Barbara Mroczko
Journal:  Int J Mol Sci       Date:  2022-08-02       Impact factor: 6.208

Review 8.  Participation of persons with dementia and their caregivers in research.

Authors:  Lori Frank; Lee A Jennings; Ronald C Petersen; Tabassum Majid; Andrea Gilmore-Bykovskyi; Lonni Schicker; Jason Karlawish
Journal:  J Am Geriatr Soc       Date:  2021-07       Impact factor: 7.538

9.  Multi-omics signature of brain amyloid deposition in asymptomatic individuals at-risk for Alzheimer's disease: The INSIGHT-preAD study.

Authors:  Laura Xicota; Farid Ichou; François-Xavier Lejeune; Benoit Colsch; Arthur Tenenhaus; Inka Leroy; Gaëlle Fontaine; Marie Lhomme; Hugo Bertin; Marie-Odile Habert; Stéphane Epelbaum; Bruno Dubois; Fanny Mochel; Marie-Claude Potier
Journal:  EBioMedicine       Date:  2019-09-03       Impact factor: 8.143

10.  Topographic Distribution of Amyloid-β, Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease.

Authors:  Joseph Therriault; Tharick A Pascoal; Melissa Savard; Andrea L Benedet; Mira Chamoun; Cecile Tissot; Firoza Lussier; Min Su Kang; Emilie Thomas; Tatsuhiro Terada; Soham Rej; Gassan Massarweh; Ziad Nasreddine; Paolo Vitali; Jean-Paul Soucy; Paramita Saha-Chaudhuri; Serge Gauthier; Pedro Rosa-Neto
Journal:  Neurology       Date:  2020-10-22       Impact factor: 9.910

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.